神经炎症性人类大脑器官使全面的药物查研究成为可能:Fingolimod及其类型聚焦
Busra Acar1, Nihan Aktas Pepe1, Aleksandra Zivkovic2
1Graduate Program of Bioengineering, Graduate School of Engineering and Science, Abdullah Gul University, 38080, Kayseri, Türkiye.
Current medicinal chemistry
|October 15, 2025
概括
这项研究开发了一种人类大脑器官 (hBO) 模型来研究神经炎症,发现fingolimod及其衍生品ST-1505在这种MS类模型中有效减少炎症并保护神经细胞.
科学领域:
- 神经科学是一个神经科学.
- 干细胞生物学 干细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 目前用于多发性硬化症 (MS) 等神经炎症疾病的模型缺乏生理相关性.
- 对于这些使人衰弱的疾病,急需先进的药物查平台.
- 人类大脑器官 (hBO) 为模拟复杂的神经疾病提供了一个有希望的途径.
研究的目的:
- 开发一个人类大脑器官 (hBO) 模型,重新总结关键的神经细胞类型.
- 在hBO模型中引起和研究神经炎症.
- 评估fingolimod及其衍生物作为潜在治疗药物的疗效.
主要方法:
- 人类大脑器官 (hBO) 是从H9干细胞生成的.
- 通过使用脂聚糖 (LPS) 诱导神经炎症.
- 使用qRT-PCR,免疫光染色 (IFS) 和ELISA分析了神经元和炎症标记物的基因和蛋白质表达.
主要成果:
- hBO成功地分化为神经元,星体细胞,微质细胞和寡质细胞.
- 治疗LPS诱导了一种MS类的神经炎症状态,由高GFAP,IBA1,NF-κB和IL-6所证明.
- 芬戈利莫德和ST-1505显示出显著的抗炎作用,减少了关键的炎症标志物并改善了神经保护指标.
结论:
- 该hBO模型有效模拟LPS诱导的神经炎症.
- 芬戈利莫德及其衍生品ST-1505在hBO模型中显示出强大的抗炎和神经保护能力.
- 大脑有机体是神经炎症疾病中药物查的可行平台.
相关概念视频
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...